Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Redhill Biopharma Ltd RDHL

Healthcare
RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204... see more

Recent & Breaking News (NDAQ:RDHL)

RedHill Biopharma Appoints Dr. June Almenoff as Chief Scientific Officer

GlobeNewswire May 28, 2019

RedHill Biopharma to Present at 2019 BIO International Convention

GlobeNewswire May 23, 2019

RedHill Biopharma Reports First Quarter 2019 Financial Results and Operational Highlights

GlobeNewswire May 7, 2019

RedHill Biopharma Submits New Drug Application for Talicia® for H. pylori Infection

GlobeNewswire May 7, 2019

RedHill Biopharma to Host First Quarter 2019 Financial Results Conference Call on May 7, 2019

GlobeNewswire April 30, 2019

RedHill Biopharma Announces Fifth U.S. Patent Covering TALICIA® for H. pylori Infection

GlobeNewswire January 17, 2019

RedHill Biopharma Announces Closing of $20 Million Underwritten Offering

GlobeNewswire December 11, 2018

RedHill Biopharma Announces Pricing of $20 Million Underwritten Offering

GlobeNewswire December 6, 2018

RedHill Biopharma Announces Proposed Public Offering of its American Depositary Shares

GlobeNewswire December 4, 2018

RedHill Biopharma Announces Positive Top-Line Results from Confirmatory Phase 3 Study with TALICIA® for H. pylori Infection

GlobeNewswire December 3, 2018

RedHill Biopharma to Present at BMO 2018 Prescriptions for Success Healthcare Conference

GlobeNewswire November 29, 2018

RedHill Biopharma Announces Presentation on YELIVA® (opaganib) for Multiple Myeloma at EORTC-NCI-AACR Symposium

GlobeNewswire November 14, 2018

RedHill Biopharma Reports Third Quarter 2018 Financial Results and Business Highlights

GlobeNewswire November 13, 2018

RedHill Biopharma to Host Third Quarter 2018 Financial Results Conference Call on November 13, 2018

GlobeNewswire November 6, 2018

RedHill Biopharma to Host Analyst and Investor Webcast on TALICIA® for H. pylori infection on October 30, 2018

GlobeNewswire October 29, 2018

RedHill Biopharma to Present at the BIO-Europe 2018 Conference

GlobeNewswire October 25, 2018

RedHill Biopharma Announces Final Patient Assessed in Confirmatory Phase III Study with TALICIA® for H. pylori Infection

GlobeNewswire October 24, 2018

RedHill Biopharma Announces Additional Data from Positive Phase III Study of RHB-104 in Crohn’s Disease at United European Gastroenterology (UEG) Week 2018

GlobeNewswire October 22, 2018

Analysis: Positioning to Benefit within ScanSource, EMCORE, PRA Group, Aqua Metals, Compass Minerals International, and Redhill Biopharma — Research Highlights Growth, Revenue, and Consolidated Results

GlobeNewswire October 16, 2018

RedHill Biopharma Late-Breaking Abstract on Positive Phase III Crohn’s Disease Study with RHB-104 to be Presented at UEG Week 2018

GlobeNewswire October 10, 2018